An observational study in Congenital Hearing Loss and Sensorineural Hearing Loss, sponsored by Harran University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged Up to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Harran University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Congenital hearing loss is one of the most common sensory disorders of childhood, and the structural, immunologic and oxidative mechanisms involved in its development are incompletely understood. This case-control study aims to evaluate serum alpha-tectorin and interleukin-10 (IL-10) levels and thiol-disulfide homeostasis in children with congenital sensorineural hearing loss (cochlear implant users and hearing aid users) compared with healthy children with normal hearing. The findings are expected to contribute to a better understanding of the mechanisms underlying congenital hearing loss and to the identification of potential diagnostic and prognostic biomarkers.
This cross-sectional case-control study is conducted at the Departments of Otorhinolaryngology and Audiology, Harran University Faculty of Medicine, Sanliurfa, Turkey. Pediatric patients with congenital sensorineural hearing loss confirmed by audiological testing (auditory brainstem response, otoacoustic emissions and/or pure-tone audiometry) are enrolled prospectively in three groups: (1) children who have undergone cochlear implantation for congenital hearing loss and actively use the implant (n=40); (2) children with congenital hearing loss who have not undergone cochlear implantation and actively use hearing aids (n=40); and (3) age- and sex-matched healthy children with normal audiological evaluation (n=40).
Written informed consent is obtained from the legal guardians of all participants, and assent is obtained from the children where appropriate. Age, sex, birth history, perinatal risk factors, comorbidities, medications, degree of hearing loss, device type and duration of device use are recorded using a standard data collection form.
Approximately 5 mL of venous blood is collected from each participant. Serum is separated by centrifugation and stored at -80 C until analysis. Serum alpha-tectorin and IL-10 levels are measured quantitatively with commercial enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturers' instructions. Thiol-disulfide homeostasis (native thiol, total thiol and disulfide levels and their ratios) is determined with an automated spectrophotometric method.
Biochemical parameters are compared between groups and analyzed in relation to clinical characteristics and the degree of hearing loss. Normality is assessed with the Kolmogorov-Smirnov and/or Shapiro-Wilk tests. Group comparisons are performed with the independent samples t-test or Mann-Whitney U test, and one-way ANOVA or Kruskal-Wallis test, as appropriate; categorical variables are compared with the chi-square or Fisher's exact test. Correlations are evaluated with Pearson or Spearman analysis, and multivariable linear regression is used to identify factors associated with biomarker levels. A p value \<0.05 is considered statistically significant.
348 studies on the registry are indexed under Hearing Loss, Sensorineural; 103 are open to participants now.
This study's planned enrollment of 120 is above the median of 70 across 86 observational studies indexed under Hearing Loss, Sensorineural.
Browse Hearing Loss, Sensorineural studies →Harran University is the lead sponsor of 64 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Children under 18 years of age with congenital sensorineural hearing loss who use cochlear implants or hearing aids, and age- and sex-matched healthy children with normal hearing, evaluated at the Otorhinolaryngology and Audiology clinics of Harran University Faculty of Medicine Hospital, Sanliurfa, Turkey.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Congenital Hearing Loss Groups (Cochlear Implant Group and Hearing Aid Group)
Healthy Control Group
Exclusion Criteria (all groups):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children under 18 years of age with audiologically confirmed congenital sensorineural hearing loss who have undergone cochlear implantation and actively use the implant (n=40).
Other: Blood sample collection
Children under 18 years of age with audiologically confirmed congenital sensorineural hearing loss who have not undergone cochlear implantation and actively use hearing aids (n=40).
Other: Blood sample collection
Age- and sex-matched healthy children under 18 years of age with normal audiological evaluation and no history of hearing loss (n=40).
Other: Blood sample collection
Collection of approximately 5 mL of venous blood for measurement of serum alpha-tectorin, interleukin-10 and thiol-disulfide homeostasis parameters; no additional intervention is applied.
Serum alpha-tectorin level
Serum alpha-tectorin concentration measured by ELISA, compared among the cochlear implant, hearing aid and healthy control groups.
Time frame: At enrollment (single blood sample)
Serum interleukin-10 (IL-10) level
Serum IL-10 concentration measured by ELISA, compared among the cochlear implant, hearing aid and healthy control groups.
Time frame: At enrollment (single blood sample)
Serum thiol-disulfide homeostasis parameters
Native thiol, total thiol and disulfide levels (umol/L) and disulfide/native thiol, disulfide/total thiol and native thiol/total thiol ratios measured by an automated spectrophotometric method, compared among the cochlear implant, hearing aid and healthy control groups.
Time frame: At enrollment (single blood sample)
Correlation of biomarker levels with degree of hearing loss
Correlation of serum alpha-tectorin, IL-10 and thiol-disulfide parameters with the degree of hearing loss (mild, moderate, severe, profound) determined by audiological evaluation, and with device type and duration of device use, in children with congenital hearing loss.
Time frame: At enrollment (single blood sample)
Plan to share: No — Individual participant data will not be shared in order to protect participant confidentiality in accordance with national personal data protection regulations (KVKK).
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Harran University